Cargando…

Liver-related effects of chronic hepatitis C antiviral treatment

More than five years ago, the treatment of hepatitis C virus infection was revolutionized with the introduction of all-oral direct-acting antiviral (DAA) drugs. They proved highly efficient in curing patients with chronic hepatitis C (CHC), including patients with cirrhosis. The new DAA treatments w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laursen, Tea L, Sandahl, Thomas D, Kazankov, Konstantin, George, Jacob, Grønbæk, Henning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304101/ https://www.ncbi.nlm.nih.gov/pubmed/32587440 http://dx.doi.org/10.3748/wjg.v26.i22.2931

Ejemplares similares

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2021)

Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects
por: Laursen, Tea L, et al.
Publicado: (2019)

No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation
por: Støy, Sidsel, et al.
Publicado: (2021)

High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study
por: Björklund, Jessica, et al.
Publicado: (2018)

Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients
por: Nielsen, Mette J., et al.
Publicado: (2015)

Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux‐en‐Y gastric bypass
por: Kazankov, Konstantin, et al.
Publicado: (2022)

The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients
por: Sandahl, Thomas Damgaard, et al.
Publicado: (2017)

Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center
por: Laursen, Tea Lund, et al.
Publicado: (2022)

Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases
por: Laursen, Tea Lund, et al.
Publicado: (2022)

Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease
por: Kazankov, Konstantin, et al.
Publicado: (2020)

Antiviral treatment in patients with hepatitis C virus-related cirrhosis awaiting liver transplantation
por: Toniutto, Pierluigi, et al.
Publicado: (2008)

Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis
por: Cuko, Liri, et al.
Publicado: (2022)

Effect of oral zinc regimens on human hepatic copper content: a randomized intervention study
por: Munk, Ditte Emilie, et al.
Publicado: (2022)

Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease
por: Saif-Al-Islam, Mahmoud, et al.
Publicado: (2021)

Antiviral Therapy in Chronic Hepatitis C Virus-related Decompensated Liver Cirrhosis – A Tightrope Walk
por: Amarapurkar, Deepak N.
Publicado: (2010)

Eczema craquelé associated with antiviral treatment for chronic hepatitis C
por: do Vale, Edla Polsinelli Bedin Mascarin, et al.
Publicado: (2017)

Antiviral Treatment for Hepatitis C Virus Infection after Liver Transplantation
por: Sugawara, Yasuhiko, et al.
Publicado: (2010)

Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD)
por: Heebøll, Sara, et al.
Publicado: (2022)

The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking
por: Kanellopoulou, Theoni, et al.
Publicado: (2016)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
por: Toshikuni, Nobuyuki
Publicado: (2017)

Highest Frequencies of Interleukin-22-Producing T Helper Cells in Alcoholic Hepatitis Patients with a Favourable Short-Term Course
por: Støy, Sidsel, et al.
Publicado: (2013)

Longitudinal Liver Stiffness Assessment in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy
por: Martinez, Stella M., et al.
Publicado: (2012)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments
por: Siphepho, Phumelele Yvonne, et al.
Publicado: (2021)

Acute-on-chronic liver failure induced by antiviral therapy for chronic hepatitis C: A case report
por: Zhong, Jiang-Li, et al.
Publicado: (2023)

Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C
por: Thabet, Khaled, et al.
Publicado: (2016)

Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response
por: Hallager, Sofie, et al.
Publicado: (2017)

Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals
por: Rodríguez-Osorio, Iria, et al.
Publicado: (2019)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data
por: Kraus, Michael R., et al.
Publicado: (2018)

Expanding Treatment Access for Chronic Hepatitis C with Task-shifting in the Era of Direct-acting Antivirals
por: Yoo, Eric R., et al.
Publicado: (2017)

Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C
por: Abdulla, Maheeba, et al.
Publicado: (2022)

Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease
por: Khoo, Tiffany, et al.
Publicado: (2021)

Recent Advances in Antiviral Therapy for Chronic Hepatitis C
por: Tamori, Akihiro, et al.
Publicado: (2016)

Use of antiviral therapy in patients with chronic hepatitis C
por: Dragomiretskaya, Natalia, et al.
Publicado: (2015)

Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents
por: Cholankeril, George, et al.
Publicado: (2017)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C
por: Gallach, Marta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7k61imlkv9e8rlmdg0amfg3fs3